The effect of omega-3 on the serum level of homocysteine in peritoneal dialysis patients

Effect of Omega-3 therapy on the serum level of Homocysteine in peritoneal dialysis patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160713028901N2

Enrollment

100

Registered

2020-09-07

Start date

2020-09-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal dialysis. Other dialysis

Interventions

Intervention 1: Intervention group: Omega-3 capsules (120 mg DHA plus 180 mg EPA) at a dose of 3000 mg per day, ie 1000 mg with each meal per day for 8 weeks. Intervention 2: Control group: Placebo, w

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: At least 18 years old ESRD patients undergoing peritoneal dialysis Informed consent to participate in this study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Homocysteine levels and inflammatory and oxidative factors. Timepoint: Before the start and at the end of week 8. Method of measurement: Homocysteine measurement kit; Other parameters will be measured according to the laboratory standard.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShirinsadat Badri

Esfahan University of Medical Sciences

badri@pharm.mui.ac.ir+98 31 3792 7068

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026